Short answer
Protalix BioTherapeutics, Inc. (PLX) filed an 8-K current report with the SEC on May 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q1 2026 results for quarter ended March 31, 2026, with accompanying business and clinical update.
Protalix BioTherapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results for quarter ended March 31, 2026, with accompanying business and clinical update
- Detailed financial figures and management commentary contained in Exhibit 99.1 press release
- Results furnished under Regulation FD, limiting Section 18 liability and registration-statement incorporation absent specific reference
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Protalix BioTherapeutics, Inc. 8-K filings
Get the next PLX 8-K as it lands
Follow PLX for push alerts, or ask the research agent what this filing means.